azd2115
Small moleculeexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2011 (NCT01283984)
Timeline
Indications
Mechanism of action
Muscarinic acetylcholine receptor M1/M5 chimeric protein inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- azd2115
- azd 2115
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02109406 | Phase 2 | May 1, 2014 | Pearl Therapeutics |
| NCT01498081 | Phase 2 | Mar 1, 2012 | AstraZeneca |
| NCT01445782 | Phase 1 | Oct 1, 2011 | AstraZeneca |
| NCT01283984 | Phase 1 | Jan 1, 2011 | AstraZeneca |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 3 | 3 | 2 | 2011 |
| Pearl Therapeutics | For profit | 1 | 1 | 1 | 2014 |
2 organizations
Page 1 / 1